Tag: cover

The dividend will cover the period through August 21, 2025

Singapore, Singapore, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The JinGangShan Asia-Pacific General Association today announced the official launch of two landmark initiatives valued at a combined SGD $43 billion, with strategic developments on Bintan Island, Indonesia, and Penang Island, Malaysia. These flagship projects—the ultra-secure Bintan Citadel and the bi-national Life Memorial Services Park—mark a significant milestone in the Association’s mission to create the world’s foremost sanctuary for safeguarding human cultural heritage and wealth for generations to come.

ATHENS, Greece, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) (the “Corporation” or “CCEC”) has called an annual meeting of shareholders to be held at the Corporation’s headquarters in Greece on September 22, 2025 at 11:30 am local time (the “Annual Meeting”). Shareholders of record at the close of business on July 25, 2025 are entitled to receive notice of, and to vote at, the Annual Meeting, or any adjournments or postponements thereof. A cover letter, formal notice of the Annual Meeting, the Corporation’s proxy statement and the accompanying Annual Report on Form 20-F are being sent to shareholders of the Corporation. Electronic copies of the materials are accessible on the Corporation’s website at http://ir.capitalcleanenergycarriers.com/. Following receipt of a proxy card, shareholders may vote their common shares by accessing www.proxyvote.com .

Experience Groundbreaking Sleep and Cellular Support Backed by Terahertz Innovation, Trusted by Wellness Experts in 2025

MONACO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Back for its fifth edition, the Monaco Smart & Sustainable Marina Rendezvous, returns on 21 and 22 September to bring together the leaders of maritime sustainability. Launched in 2021 and organised by M3 Monaco with the support of the Prince Albert II Foundation and the Yacht Club de Monaco, the event has become a meeting point for over 250 professionals in the maritime sector – investors, architects, startups, and marina managers – all committed to the ecological transformation of nautical infrastructures.

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants included in the units and pre-funded units have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol “BIVIW” on August 8, 2025. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $2.50 per share and will expire five years from the date of issuance. Each Pre-Funded Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock and may be exercised at any time until exercised in full. The common stock (or Pre-Funded Warrants in lieu thereof) and Warrants can only be purchased together in the offering but will be issued separately. The Company has granted the underwriter a 45-day option to purchase up to an additional 900,000 shares of common stock and/or Pre-Funded Warrants and/or Warrants, or any combination thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.